Sanofi Scouting For Cancer Deals, Diabetes Drugs Miss In 1Q
Sanofi is seeking asset deals to bulk up its oncology pipeline in 2017 – specifically, the big pharma is on the lookout for oncology compounds with potential in prostate cancer or breast cancer, the company highlighted during its first-quarter earnings call.
You may also be interested in...
After reporting yet another quarter of disappointing sales, Amgen and Sanofi/Regeneron look forward to better performance now that outcomes data are out, but payers may not be up for easing hurdles enough.
A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus' Phase II NASH candidate and picks up a CAR-T candidate from Celyad, while Shire adds to its dry eye franchise in deal with Parion.
Health care funding in the first half of 2020 reached $10.4bn, according to a mid-year report from Silicon Valley Bank, nearly matching 2019’s full-year record. As well as the COVID-19 pandemic though, other global events, such as the US election, could become distractions in the second half of the year.